BiotechTube

Prothrombin complex concentrate (Human) + Fresh frozen plasma (FFP)

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Bleeding

Conditions

Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures, Prothrombin Complex Concentrates, Fresh Frozen Plasma

Trial Timeline

Aug 1, 2016 → Jan 1, 2022

NCT ID
NCT02557672

About Prothrombin complex concentrate (Human) + Fresh frozen plasma (FFP)

Prothrombin complex concentrate (Human) + Fresh frozen plasma (FFP) is a approved stage product being developed by CSL for Bleeding. The current trial status is completed. This product is registered under clinical trial identifier NCT02557672. Target conditions include Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures.

What happened to similar drugs?

6 of 20 similar drugs in Bleeding were approved

Approved (6) Terminated (2) Active (12)
🔄Elagolix + Estradiol /norethindrone acetate (E2/NETA)AbbViePhase 3
🔄Esomeprazole Na + Cimetidine + Esomeprazole MgAstraZenecaPhase 3
✅Tamoxifen + Placebo + Tamoxifen (open label)MerckApproved
✅Placebo + CurcuminMerckApproved
✅Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon) + Etonogestrel 68 mg subdermal implantMerckApproved
🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
❌eptacog alfa (activated) + placeboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02557672ApprovedCompleted

Competing Products

20 competing products in Bleeding

See all competitors
ProductCompanyStageHype Score
60mg edoxaban + 180mg edoxaban + 50 IU/kg Beriplex P/N + 25 IU/kg Beriplex P/N + 10 IU/kg Beriplex P/NDaiichi SankyoPhase 1
29
Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placeboAbbViePhase 2
35
Elagolix + Placebo + Estradiol/Norethindrone acetate (E2/NETA) + Estradiol + ProgesteroneAbbViePhase 2
35
Elagolix + Estradiol /norethindrone acetate (E2/NETA)AbbViePhase 3
40
Risk of selected safety eventsAstraZenecaPre-clinical
26
AnticoagulantAstraZenecaPre-clinical
22
Esomeprazole Na + Cimetidine + Esomeprazole MgAstraZenecaPhase 3
40
Tamoxifen + Placebo + Tamoxifen (open label)MerckApproved
43
Placebo + CurcuminMerckApproved
43
Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon) + Etonogestrel 68 mg subdermal implantMerckApproved
39
Octreotide LAR DepotNovartisPhase 1
29
activated recombinant human factor VIINovo NordiskPre-clinical
26
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
40
catridecacog + recombinant factor XIIINovo NordiskPhase 1
29
eptacog alfa (activated) + placeboNovo NordiskPhase 3
32
activated recombinant human factor VII + activated recombinant human factor VIINovo NordiskPhase 1
29
activated recombinant human factor VIINovo NordiskPhase 2
35
autologous stored plateletsNovo NordiskPhase 2
35
turoctocog alfa pegolNovo NordiskPhase 3
40
recombinant factor XIIINovo NordiskPre-clinical
26